Fred Vogt, Iovance Biotherapeutics

from Being a Life Sciences Leader · host Life Sciences Pennsylvania

Send us Fan MailThis episode features Fred Vogt, Interim CEO at Iovance Biotherapeutics, recipient of the 2024 Patient Impact Award. In this episode, Fred shares the journey behind AMTAGVI - the first FDA approved tumor infiltrating lymphocyte (TIL) therapy. Learn about the clinical trial process, how they brought this groundbreaking treatment to market, the impact the Iovance team has on the life sciences industry and how the state of Pennsylvania is supporting Iovance's efforts to treating patients.

Episode metadata supplied by the publisher feed · Published Feb 26, 2025

Embed this episode

Attribution link and audio player

Ready to play

Fred Vogt, Iovance Biotherapeutics

0:00 28:41

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Being a Life Sciences Leader?

This episode is 28 minutes long.

When was this Being a Life Sciences Leader episode published?

This episode was published on February 26, 2025.

Can I download this Being a Life Sciences Leader episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!